NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

By João L. Carapinha

October 10, 2024

The article from the National Institute for Health and Care Excellence (NICE) titled “NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer” highlights crucial details regarding the evaluation and potential use of elacestrant breast cancer therapy. Elacestrant is specifically under review for its effectiveness in treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer with an activating ESR1 mutation, which complicates hormone therapies.

Key Points

Condition and Treatment

– Elacestrant is being considered for treating oestrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation. This particular mutation can cause hormone therapies to stop working, leading to cancer progression.

Mechanism of Action

– As an oestrogen receptor degrader, elacestrant binds to and degrades oestrogen receptors, blocking oestrogen’s ability to bind to breast cancer cells and promote their growth.

Draft Guidance

– NICE has issued draft guidance that does not currently recommend elacestrant for this type of advanced breast cancer due to uncertainty in the evidence. This draft is open for public consultation until 22 October 2024.

Evidence and Uncertainty

– The evidence indicates that elacestrant may improve the time before the breast cancer worsens compared to standard care. However, there is considerable uncertainty surrounding these estimates. NICE has requested further analysis from the company to clarify and address this uncertainty.

Patient Eligibility

– It is estimated that about 1,000 individuals could be eligible for treatment with elacestrant breast cancer therapy.

Use of Severity Modifier

– NICE is examining whether to apply a severity modifier, which would give additional weight to the benefits of medicines based on the severity of the disease. This evaluation will continue at the committee’s next meeting on 12 November 2024.

Company and Stakeholders

– The company involved, Menarini Stemline, is collaborating with NICE to address the uncertainties in the evidence for elacestrant. Various patient, carer, and professional groups are also participating in the consultation process.

Context of Previous Recommendations

– Historically, around three-quarters (76%) of topics that were not initially recommended by NICE at the draft stage ended up receiving a positive recommendation before the final guidance was published. This trend suggests that there remains a potential for elacestrant to be recommended if the uncertainties can be successfully resolved.

Reference url

Recent Posts

implantable glucose device
         

T1 Diabetes Care with an Implantable Glucose Device

🚀 Are we on the brink of a diabetes breakthrough?

A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.

Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!

#SyenzaNews #HealthTech #HealthEconomics #Innovation

federated learning governance
      

Federated Learning Governance in Healthcare: A Framework for Ethical and Effective Implementation

🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?

In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.

Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!

#SyenzaNews #AIinHealthcare #DigitalHealth

Cecolin 9 HPV vaccine
        

Cecolin 9 HPV Vaccine: A Game Changer for Cervical Cancer Prevention in China

🌍 Did you know that China has just achieved a historic milestone in the fight against cervical cancer?

The approval of the Cecolin 9 HPV vaccine, the first domestically developed 9-valent HPV vaccine, marks a transformative moment for public health, enhancing access and affordability across the nation. This development not only meets global health goals but also reshapes the landscape of cervical cancer prevention in China.

Curious to learn how this advancement is set to impact vaccination efforts and healthcare economics? Dive into the full article for deeper insights!

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.